Hepatitis C: why the low uptake of boceprevir and telaprevir?
نویسندگان
چکیده
منابع مشابه
Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
BACKGROUND Hepatitis C virus (HCV) is the most common chronic bloodborne illness in the United States. The incidence of acute hepatitis C in the United States peaked near 50,000 cases in the late 1980s but has stabilized since 2003 to less than 5,000 cases annually. The combination of pegylated interferon (peginterferon) and ribavirin has been the standard recommended treatment for HCV. Proteas...
متن کاملBudget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
BACKGROUND Boceprevir and telaprevir have recently showed dramatically better treatment outcomes than conventional PEGylated interferon plus ribavirin for the treatment of hepatitis C virus genotype 1, but the average cost per patient is unknown. METHODS In the UK context, we performed a budget impact analysis to estimate the average per patient cost of adding boceprevir or telaprevir to PEGy...
متن کاملBoceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.
Effective management of adverse events (AEs) is important to prevent treatment discontinuation and optimize hepatitis C virus infection eradication rates. The addition of direct-acting antiviral agents, telaprevir (TVR) or boceprevir to pegylated interferon (PEG-IFN) and ribavirin (RBV) represents a new era of therapy associated with an improvement in treatment response rates and an impairment ...
متن کاملVictory and defeat at Heraclea - treating hepatitis C infection following liver transplantation with telaprevir and boceprevir.
HCV associated liver disease continues to be the most common indication for liver transplantation in the West. Although the impact of HCV infection varies substantially between recipients, allograft failure secondary to recurrence of HCV infection is the most frequent cause of death and graft failure in HCV infected recipients. Attenuating the impact of HCV on posttransplant patient and graft s...
متن کاملBeyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection.
The addition of the hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir to peginterferon alfa with ribavirin therapy has increased cure rates in HCV infection. Numerous other direct-acting antivirals (DAAs) are in advanced stages of development, including next-generation protease inhibitors, nonstructural protein (NS) 5A inhibitors, and nonnucleoside and nucleos(t)ide NS5B pol...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Prescriber
سال: 2012
ISSN: 0959-6682
DOI: 10.1002/psb.992